RNA interference mediated inhibition of myostatin gene...

Details RNA interference mediated inhibition of myostatin gene... RNA interference mediated inhibition of myostatin gene...

2011-07-12

2011-07-12

Whiteman, Brian (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

Reexamination Certificate

active

07977472

ABSTRACT:
This invention relates to compounds, compositions, and methods useful for modulating myostatin (GDF8) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of myostatin genes.

REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 6468535 (2002-10-01), Lee et al.
patent: 6723706 (2004-04-01), Uhlmann et al.
patent: 7022828 (2006-04-01), McSwiggen
patent: 7300922 (2007-11-01), Sullenger et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0180351 (2004-09-01), Giese et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: 90/14090 (1990-11-01), None
patent: 94/01550 (1994-01-01), None
patent: 99/13886 (1999-03-01), None
patent: 99/32619 (1999-07-01), None
patent: 99/49029 (1999-09-01), None
patent: 00/44895 (2000-08-01), None
patent: 00/44914 (2000-08-01), None
patent: 01/36646 (2001-05-01), None
patent: 01/96584 (2002-03-01), None
patent: 02/22636 (2002-03-01), None
patent: 02/44321 (2002-06-01), None
patent: 03/064626 (2003-08-01), None
BPAI decision Reexamination 90/008,177 dated May 26, 2009, pp. 1-39.
Gonzalez-Cadavid et al. (PNAS 95:14938-14943, 1998).
Parrish et al. (Mol. Cell 6: 1077-1087, 2000).
Lehninger Principles of Biochemistry, 4thedition WH Freeman and Company, New York 2005, pp. 921-922.
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,” Oligonucleotides 13(5):303-312 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,” Methods 26 (2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,” Nature 411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,” EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,” Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature 391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,” Nucleic Acids Research Supplement 2:251-252 (2002).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,” Biochemical and Biophysical Research Communications 295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,” Biochemical and Biophysical Research Communications 281:639-644 (2001).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions 295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,” Genes and Development 13 (24):3191-3197 (1999).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed on Aug. 28, 2009 for U.S. Appl. No. 12/185,678, 16 pages.

Affiliated with

Also associated with

Rating

RNA interference mediated inhibition of myostatin gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RNA interference mediated inhibition of myostatin gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of myostatin gene... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2736567